Tempus AI (NASDAQ:TEM) Shares Gap Down - Time to Sell?

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) shares gapped down prior to trading on Tuesday . The stock had previously closed at $49.87, but opened at $47.79. Tempus AI shares last traded at $46.51, with a volume of 2,005,129 shares trading hands.

Analysts Set New Price Targets

TEM has been the subject of several research analyst reports. TD Cowen reaffirmed a "buy" rating and set a $74.00 price target (up previously from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Morgan Stanley boosted their target price on Tempus AI from $50.00 to $60.00 and gave the stock an "overweight" rating in a research report on Thursday, March 6th. JPMorgan Chase & Co. cut shares of Tempus AI from an "overweight" rating to a "neutral" rating and increased their price target for the company from $50.00 to $55.00 in a research report on Tuesday, February 25th. Piper Sandler decreased their price target on shares of Tempus AI from $70.00 to $55.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Tempus AI in a research note on Tuesday, February 25th. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $61.18.

Tempus AI Stock Up 6.9 %

The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The firm's 50 day moving average price is $56.07 and its 200 day moving average price is $51.45.

Remove Ads

Insider Activity at Tempus AI

In related news, COO Ryan Fukushima sold 20,000 shares of Tempus AI stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $39.61, for a total value of $792,200.00. Following the sale, the chief operating officer now owns 982,442 shares in the company, valued at $38,914,527.62. The trade was a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO James William Rogers sold 23,030 shares of the company's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $45.97, for a total transaction of $1,058,689.10. Following the completion of the transaction, the chief financial officer now owns 164,750 shares of the company's stock, valued at $7,573,557.50. This trade represents a 12.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,598,969 shares of company stock worth $317,194,162 in the last 90 days.

Institutional Trading of Tempus AI

Several institutional investors and hedge funds have recently bought and sold shares of TEM. First Horizon Advisors Inc. bought a new position in shares of Tempus AI in the 3rd quarter worth approximately $30,000. Operose Advisors LLC bought a new stake in shares of Tempus AI during the fourth quarter valued at approximately $25,000. Farther Finance Advisors LLC purchased a new stake in Tempus AI in the fourth quarter worth $34,000. Prestige Wealth Management Group LLC raised its holdings in Tempus AI by 910.4% in the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock worth $36,000 after purchasing an additional 965 shares in the last quarter. Finally, NewEdge Advisors LLC purchased a new position in Tempus AI during the fourth quarter valued at $49,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.